Magic mushrooms in palliative care: Clinicians are keen but ill-equipped
Once relegated to the counterculture, psilocybin—the psychoactive compound in "magic mushrooms"—has been receiving renewed scientific attention. A growing body of research points to its potential for treating depression, addiction and end-of-life distress, prompting several countries to loosen regulations and greenlight clinical use.
Psilocybin, found in magic mushrooms, has garnered renewed scientific interest for its potential therapeutic benefits. A recent study has explored Canadian healthcare professionals' attitudes towards its use in palliative care. Despite its promising results in reducing depression, anxiety, and existential distress, fewer than half of the surveyed clinicians felt adequately informed about the drug's risks and benefits.
A significant hurdle, according to the study, is the shortage of trained professionals capable of administering the therapy safely. This shortage stems from the absence of standardized training programs and recognized certifications. Despite this, the majority of clinicians remain supportive of integrating psilocybin-assisted therapy into palliative care, recognizing its promise in addressing treatment-resistant symptoms.
However, they highlight the need for better training and certification to ensure safe and equitable implementation.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
